One year of treatment with dapirolizumab pegol reduced fatigue and disease activity in people with SLE in a Phase 3 trial.

Magnetic resonance imaging (MRI) findings such as inflammatory-type lesions and myelopathies are significantly associated with attribution of neuropsychiatric (NP) events to systemic lupus ...

A team studied the differences between monogenic and nonmonogenic lupus nephritis and the predictors of end-stage kidney disease.

Dapirolizumab pegol, a novel CD40L inhibitor, is superior to placebo for achieving low disease activity and remission in ...

Objective This study aims to evaluate the role of antiphospholipid antibodies (aPLs) in patients with SLE with heart valve ...

New research by Swansea University and Cambridge University has revealed the causes and devastating impacts of delays, which ...

This article explores the complex roles of cytokine networks in the development and progression of autoimmune diseases.

The systemic lupus erythematosus (SLE) treatment pipeline is experiencing unprecedented expansion, driven by increasing disease awareness, rising pre ...

Flare and persistently active disease are prevalent in a multinational cohort study of patients with systemic lupus erythematosus, with some having persistently active disease without flare.

CD19-CAR T-cell treatment is a novel option of deep B cell depletion with promising results across different rheumatologic ...

Therapies involving B-cell depletion targeting CD19 or BCMA have shown efficacy in the treatment of B-cell malignancies. Recently, this approach has shown efficacy in the treatment of autoimmune ...